News

Clinical Trials Arena on MSN23h
Diakonos Oncology secures $20m for Phase II trial of glioblastoma treatment
Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...
Le Lézard20h
Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) for the Treatment of Glioblastoma at the ASCO 2025 Annual Meeting
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...
Kalkine Media7h
How Moderna Went From Pandemic Hero to Vaccine Victim
The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules. Continue Reading View Comments "Kalkine Media dolor sit amet, ...